According to guidelines from the American College of Physicians, pharmacologic treatment should be offered to all women with known osteoporosis to reduce the risk for hip and vertebral fractures. Treatment options include alendronate, risedronate, zoledronic acid, or denosumab.
Estrogen or estrogen plus progestogen or raloxifene should not be used for the treatment of osteoporosis in postmenopausal women owing to the risk for potentially adverse outcomes. Selective estrogen receptor modulators can be considered.
Bisphosphonates are the most frequently used agents for osteoporosis. According to guidelines from the American Association of Clinical Endocrinologists, in patients with high fracture risk, a bisphosphonate holiday should be considered after 6-10 years of treatment. For patients who are not at high risk for fracture, a holiday may be considered after 5 years of use.
Learn more about the treatment of osteoporosis.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Herbert S. Diamond. Fast Five Quiz: Osteoporosis Prevention and Treatment - Medscape - Dec 10, 2020.